All articles tagged with #medical devices
Maggot therapy uses medicinal maggots to selectively remove dead tissue from wounds, offering a painless, potentially cheaper alternative for patients who can’t undergo surgery; though FDA-cleared and used by some centers, adoption is limited by reimbursement gaps, limited high-quality data, and the “yuck factor.”
At-home sleep apnea tests offer an affordable, FDA-cleared route to diagnosis with a clinician-reviewed report, enabling a fast start to CPAP therapy; CPAP machines are now smaller and quieter, often improving sleep, energy and mood, and even relationships, with Sleep Week promotions and store credits encouraging the at-home option.
Danaher will acquire Masimo for $180 per share in cash, valuing the deal at about $9.9 billion. The boards have approved the transaction, Masimo will become a standalone business unit and brand within Danaher’s Diagnostics segment, and the deal is expected to close in the second half of 2026 subject to regulatory approvals and other customary closing conditions.
Danaher is closing in on a roughly $10 billion deal to acquire Masimo, a leading medical-device maker, signaling a major expansion of its health-technology portfolio.
Reuters documents safety concerns with AI-enabled medical devices, notably Johnson & Johnson’s Acclarent TruDi Navigation System, which added AI in 2021 and is tied to malfunctions and injuries, including misidentified anatomy and strokes, with several lawsuits alleging AI contributed to harm. The FDA reports thousands of AI-powered device alerts and dozens of recalls as regulators struggle to keep pace with rapid AI adoption in medicine, highlighting ongoing questions about safety and oversight as AI expands in the field.
Boston Scientific signed a cash-and-stock deal to acquire Penumbra for about $14.5 billion, valuing Penumbra at $374 per share and aiming to close later this year pending approvals. Penumbra’s portfolio spans neurovascular and vascular devices, including thrombectomy systems, potentially broadening Boston Scientific’s growth in high-potential markets. Financing consists of roughly 73% cash and 27% stock, with an expected near-term EPS dilution followed by accretion as synergies materialize.
Boston Scientific plans to acquire Penumbra for about $14.5 billion in cash and stock, gaining Penumbra’s thrombectomy and embolization devices to broaden its vascular portfolio. The deal values Penumbra at $374 per share and is expected to close in 2026 pending shareholder and regulatory approvals, with Penumbra generating about $1.4 billion in revenue for 2025. Analysts say the price is fair and the acquisition aligns with a trend of medtech consolidation.
Vagus nerve stimulation (VNS) involves using devices to send electrical pulses to the vagus nerve, which can be done invasively or through skin patches, and is used for conditions like epilepsy and cluster headaches. While some users report benefits such as increased energy and improved sleep, scientific evidence is limited, and the effectiveness of these devices remains uncertain, with some experts suggesting placebo effects may play a role.
The FDA has removed Theresa Michele, the longtime director of the Office of Nonprescription Drugs, from her position and transferred her to a leadership role in the medical devices center, amid recent leadership changes at the agency.
The Trump administration has initiated investigations under Section 232 into imports of robotics, industrial machinery, and medical devices, potentially leading to new tariffs aimed at boosting domestic manufacturing and reducing reliance on foreign supplies, especially in critical sectors like healthcare and industrial equipment.
Verily, Alphabet's life sciences division, is shutting down its medical device program to focus more on AI and data infrastructure, amid ongoing cost-cutting and layoffs across the company as it shifts resources towards artificial intelligence development.
The article showcases bizarre and outdated medical devices and treatments from the past, highlighting how far modern medicine has come in terms of safety, effectiveness, and understanding of health, from early surgical methods to advanced diagnostic technology and vaccines.
Abbott Laboratories' stock fell nearly 6% after lowering its 2025 sales outlook following a mixed Q2 report, despite beating revenue and earnings estimates; growth in medical devices and established pharmaceuticals was strong, but diagnostics underperformed, leading to a cautious outlook and a premarket decline.
Mattel has launched a Barbie doll with Type 1 diabetes, equipped with a glucose monitor and insulin pump, to promote inclusivity and awareness of the condition among children, in partnership with Breakthrough T1D and reflecting a broader effort to represent diverse health experiences in toys.
China has imposed restrictions on EU medical device imports exceeding 45 million yuan in response to the EU's recent bans on Chinese companies participating in public tenders, escalating trade tensions between the two economies.